Aguilla advfn2 Aug 2023 18:10
Very good summary
Having missed the boat on covid testing, Genedrive has now come up with 2 tests which offer exciting possibilities.
One, the MT-RNR1 test, is a test that can help prevent new born babies from going deaf if treated with a common antibiotic and is now being used in routine clinical practice in maternity settings at Manchester University NHS Foundation Trust (MFT). It is estimated that approximately 1,700 babies a year will be tested at MFT, which has so far prevented the hearing loss of six babies in Greater Manchester since the pilot in 2021 through to the implementation of the test in 2022. The new swab test technique replaces a test that traditionally took several days and is the first use of a rapid point of care genetic test in acute neonatal care. Approximately 350 nurses have already been trained to use the genetic testing machine across MFT.
While MFT is the first trust to routinely use the test, other NHS trusts in Greater Manchester will soon follow. Bolton NHS Foundation Trust, Northern Care Alliance NHS Foundation Trust, Tameside and Glossop Integrated Care NHS Foundation Trust and Wrightington, Wigan and Leigh Teaching Hospitals NHS Foundation Trust are also set to introduce the revolutionary test in 2023.
The second test, CYP2C19 ID Kit, is a molecular point-of-care test for rapid CYP2C19 genotyping. It is proposed to be used to identify which patents may or may not respond to mainline antiplatelet therapy following ischemic stroke. The test is expected to provide a result in about an hour in order to ensure prompt and correct treatment of stroke patients on the same day. It is often desirable to give antiplatelet therapies within 24 hours of admission to hospital post an ischemic stroke, and a rapid on-site point of care test would ensure this is possible since lab-based test can take days or weeks. This test is still in development but launch is expected by December of this year.
Sign In
Follow the stocks
